2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06G.13 TP53 Somatic Mutation and its Association with Clinicopathological Parameters and Long-Term Clinical Outcome in Non-Squamous NSCLC Patients

EP.06G.13 TP53 Somatic Mutation and its Association with Clinicopathological Parameters and Long-Term Clinical Outcome in Non-Squamous NSCLC Patients

Back to course

Pdf Summary

The study titled "TP53 Somatic Mutation and its Association with Clinicopathological Parameters and Long-Term Clinical Outcome in Non-Squamous NSCLC Patients" by João Pedro Costa Apolinário explores the impact of TP53 somatic mutations on non-small cell lung carcinoma (NSCLC), particularly non-squamous subtypes, focusing on their prevalence and connection to clinical outcomes.<br /><br />NSCLC is a leading cause of cancer mortality worldwide, and p53 alterations are significant as they can influence treatment resistance and decisions. This research focuses specifically on patients diagnosed with non-squamous NSCLC who have undergone a full molecular panel. Excluded from this analysis are patients with specific STK11 and KEAP1 mutations, aiming to evaluate other risk factors linked to overall survival (OS) and progression-free survival (PFS).<br /><br />Key findings indicate a significant presence of TP53 mutations, particularly where 28.2% of patients had TP53 mutations, with some overlaps with RAS mutations. The study determined that these mutations are associated with poor clinical outcomes, notably lower OS and PFS in certain contexts. For example, patients with a tumor mutation burden (TMB) greater than 10 showed a median OS significantly lower than those with TMB less than 10. The same discrepancy was observed in patients with unusual metastatic sites compared to more typical presentations. <br /><br />Despite some associations, the role of TP53 mutations in generating resistance to therapies, particularly tyrosine kinase inhibitors (TKIs), was notably linked to poorer responses, though not conclusively tied to immunotherapy resistance. These results point to the necessity for further exploration to solidify the connection and implications of TP53 mutations in clinical practices for treating NSCLC, emphasizing the need for larger cohort studies to solidify these findings.

Asset Subtitle

João Pedro Apolinário

Meta Tag

Speaker João Pedro Apolinário

Topic Pathology and Biomarkers

Keywords

TP53 mutation

non-squamous NSCLC

clinicopathological parameters

long-term clinical outcome

tumor mutation burden

overall survival

progression-free survival

tyrosine kinase inhibitors

RAS mutations

João Pedro Costa Apolinário